Cancer drug developer obtains $32.5M in private placement

05/3/2013 | American City Business Journals

Celator Pharmaceuticals, a New Jersey-based firm specializing in cancer drugs, secured $32.5 million in a private placement led by Valence Life Sciences. Proceeds will go toward the late-stage trial of CPX-351 liposome injection, the company's lead drug candidate for secondary acute myeloid leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI